Ipsen's growth, technology and R&D engines fully at work

Jefferies – Global SpecPharma & European Healthcare Conference 5th October – London



Mr Pierre Kemula – Investor Relations Officer




Disclaimer

This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated in the summary information. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably given that a new product can appear to be promising at a preparatory stage of development or after clinical trials but never be launched on the market or be launched on the market but fail to sell notably for regulatory or competitive reasons. The Group must deal with or may have to deal with competition from generic that may result in market share losses, which could affect its current level of growth in sales or profitability. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this presentation to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based unless so required by applicable law.

All product names listed in this document are either licensed to the Ipsen Group or are registered trademarks of the Ipsen Group or its partners.

Ipsen today : a global biotech specialty pharma...

	SPECIALTY CARE A global business to GROW	PRIMARY CARE OPTIMISE presence		
24%	ONCOLOGY Decapeptyl®	GI	18%	A trar
20%	ENDOCRINOLOGY Somatuline [®] , Nutropin [®] , Increlex [®]	Cognitive disorders	11%	transactional
16%	NEUROLOGY Dysport [®] , Apokyn [®]	Cardiovascular	7%	nal mode
-	HEMATOLOGY INSPIRATION partnership	Others*	4%	<u>e</u>
	Over €1 billion in t	otal sales in 2009		
	A unique innovation driven and R&D expense			
3		* Other Pharmaceutical products	(Primary Care	e) and Drug Rela





2008 rounded Market shares, except for Somatuline® in the US: 4Q09

Market shares are for (i) Dysport[®] in medical indications (ii) Decapeptyl in prostate cancer (China gynecology only) and (iii) Somatuline in Acromegaly only. * In the US, market share in patients treated by endocrinologists and in pituitary centers



... with Specialty care driving the Group's dynamic growth...





All growth rates exclude foreign exchange impacts



... outgrowing its main competitors¹

H1 2010 sales of Decapeptyl[®] : +11.2%²

H1 2010 sales of Dysport[®] : +13.2%²

H1 2010 sales of Somatuline[®] : +20.2%²

H1 2010 sales of NutropinAq[®] : +22.0%²



Ipsen is gaining market shares with its 4 flagship products globally


2 Year-on-year first half growth at constant currency

5



7

Today, a reinforced profile




Confirming Ipsen's biotech specialty care profile

A truly differentiated R&D



The fundamentals : restoring physiological balance




Therapeutic corollary : restore physiological levels, no more, no less

9

8IPSEN

... applied to well defined disease areas and indications



Focused, aligned, synergies across therapeutic areas

Example of differentiation : Somatuline[®] Depot

		Sandostatin LAR®	Somatuline [®] Autogel [®]
Administration		2.0 ml Intramuscular	0.3 ml – 0.5 ml Subcutaneous
Presentation		Powder vial + solvent filled syringe + 2 needles	Pre-filled syringe
Injection technique		10 steps needed to reconstitute	Ready to use Self administration*
For what reasons woul	d you	ı prescribe Somatuline [®] Depot to y	our acromegaly patients?**
Pre-filled syringe / no reco	onstit	ution needed	87%
More convenient because	the p	atient can self inject	83%
Saves staff time and reso	urces	(self-injection possible at home) 65%	
Improved patient complia (less injection site pain due to sho	nce rter nee	dle and smaller volume) 61% % of physicians	



Somatuline® Depot: A self administration syringe, an improved quality of life


* In selected countries

11

** Study Sample: A total of 50 US endocrinologists completed a 30-minute online questionnaire between April 4 - 17, 2008 25 High Volume Endocrinologists: Endocrinologists who see 11 or more acromegaly patients in a year 25 Low Volume Endocrinologists: Endocrinologists who see between 5-10 acromegaly patients in a year


A strong commercial presence







... leading to continuous, fast development outside historical G5



Evolution of Group sales outside G5







...with significant achievements in less than two years


- FDA approval of 2 major products : Somatuline[®] and Dysport[®]
- 2009 sales of €45.7 million, growing 60%+ year-on-year
- In H1 2010 sales of €27.5 million, growing 30%+ year-on-year
- Today, Ipsen's 6th largest affiliate



...delivering ~25% sales CAGR over the past 5 years



- Sales force ~200
- Covering top tier 1 & 2 cities and entering T3²
- ~15%³ market share
- Non EDL⁴ market (T1 & T2) growth slowing down
- EDL² segment (T3) to grow > 50% in volume





- Covering >100 top tier cities
- Endometriosis:
 - · Launched in 1999
 - Market CAGR 10-14> 20%³
 - Achieved leadership
- Prostate cancer:
 - 3-month launched in Q1 2010
 - First in market
 - Market CAGR 10-14 > 25%³

A portfolio built on solid historical gastroenterology pillar, now boosted by fast growing specialty care franchise


FIPSEN Innovation for patient care

A strong presence in Russia, the fastest growing Eastern European market...

- Presence since 1993
- HQ in Moscow. Total staff of ~200 employees
- ~€50 m 2009 sales
- Today, Ipsen's 7th largest affiliate
- Sales force regional teams focused on 30+ major cities
- Strong franchises among neurologists, gynecologists, onco-urologists, pediatricians
- Solid expertise in distribution management, a key success factor in a highly complex and fragmented market




19




A balanced portfolio with solid foundation of Primary Care franchise and fast-growing Specialty Care sales

An strong partnerships strategy





....to build a unique franchise covering all needs in hemophilia...



A recombinant product in each segment of the hemophilia market

23


SIPSEN Innovation for patient care


Building value with a strong R&D pipeline





Somatuline[®] offers significant life cycle growth opportunities





Complete results available in H2 '10

Phase III to start




Neurology: Dysport indications



27



A rich and balanced R&D portfolio...








Back up



Ipsen will continue to expand geographic reach by developing its specialty care products for international markets...






SIPSEN

A rich and balanced R&D portfolio...

SIPSEN //////




Half-year 2010 financial performance in line with full year objectives



Specialty care strongly drives sales growth in H1 2010


Sales in € million

%IPSEN






Sales are driven by regions beyond G5



- European G5 Specialty care sales growth offset by tougher competitive environment, notably in French Primary care
- Other European countries Dynamic growth throughout with favourable 2009 basis (Eastern Europe crisis)
- North America Strong growth driven by the penetration of 4 products
- ROW Strong growth, notably in China with the launch of Decapeptyl[®] 3M in the treatment of prostate cancer

Other Revenues evolution

FIPSEN




Royalties Received Excluding the proceeds of the Bayer settlement, royalties received in H1 2010 grew 4x to €2.1m from €0.5m


Milestones Primarily income from the agreements with Medicis, Galderma, Recordati and Roche. Additional income from Menorini

Additional income from Menarini (Adenuric[®]) and Inspiration Biopharmaceuticals (OBI-1)

Other revenues
 invoicing of OBI-1's development costs
 to Inspiration Inc. (€6.8 m) and income
 from the Group's Co-promotion
 contracts in France




Recurring adjusted Operating Income¹ has improved by 20.2%



39

81PSEN /////

NOTE 1 : Defined as reported operating income before any impacts related to purchase price accounting in connection with the Group's acquisitions and before any potential non-recurring items.





Balance sheet evolution

Assets	5		
- In million euros	31 Dec 09	30 Jun 10	
Goodwill	290.2	306.5	Ec
Investment in associated companies (Incl. Goodwill Inspiration Inc.)		68.4	
Property. plans & equipments	251.8	264.2	М
Intangible assets	237.0	264.1	Т
Other non-current assets	145.5	191.7	Lo
Total non-current assets	924.5	1094.9	Ot lia
Total current assets	652.4	610.6	O
Incl. cash and cash equivalents	218.6	167.3	Inc
Assets / discontinued operations	0.0	0.0	Li op
Total assets	1 576.9	1 705.5	Т
Net Cash ⁽¹⁾	185.6	142.1	


Liabi	lities	
- In million euros	31 Dec 09	30 Jun 10
Equity	982.6	1 075.0
Minority interests	1.7	1.7
Total equity	984.3	1 076.7
Long-term financial debts	12.2	15.7
Other non-current liabilities	270.3	315.2
Other current liabilities	308.1	295.9
Incl. Short-term debts	21.4	10.0
Liabilities / discontinued operations	2.0	2.0
Total Liabilities	1 576.9	1 705.5

(1) Net cash: cash. cash equivalents and securities held for sales minus bank overdrafts. bank borrowings and other financial liabilities plus or minus derivative financial instruments

41



Significant increase of partnership related deferred revenues



Main milestones cashed-in over the period

H2 2009 Galderma: €14m upon MA and launch for Azzalure[®]

October 2009 Menarini: €20m upon signing of partnership for Adenuric[®]

January 2010 Inspiration: \$50m upon agreement on OBI-1 licence (non cash)

March 2010 Menarini: €18m upon launch of Adenuric[®]



Cash flow statement

	30 Jun 09	30 Jun 10	
- In million euros			
Cash Flow before change in working capital	121.5	98.6	
- Deferred revenue from Inspiration (non cash)		35.5	
 Increase / Decrease in working capital (except non cash deferred revenue from Inspiration) 	25.7	0.6	 Receivable : - €37.8n Payables : - €5.1m
Net cash flow generated by operating activities	147.2	134.7	 Income tax : + €52.7r
Investment in Tangible and Intangible assets	(25.1)	(25.3) \	■ Others : - €8.3m
Investments in associated companies (Inspiration)	-	(57.7)	\mathbf{N}
Convertible note subscriptions (Inspiration)	-	(35.5)	\mathbf{A}
Others	(7.3)	(5.8)	Tangible assets : - €1
Net cash flow used in investing activities	(32.4)	(124.3)	Intangible assets : - €
Net change in borrowings	(159.4)	(0.2)	
Dividends paid	(58.2)	(62.3)	
Others	-	(0.9)	
Net cash flow used in financing activities	(217.6)	(63.4)	
Discontinued operations	(0.2)	-	
Change in cash and cash equivalent	(103.0)	(53.0)	
Impact of exchange rate fluctuations	4.8	11.7	
Closing cash & cash equivalents	139.1	164.1	
Closing Net Cash ⁽¹⁾	118.9	142.1	
43			urities held for sales minus bank ove as plus or minus derivative financial i



In summary

Strong performance of Specialty Care sales: +14.4%¹ y-o-y

Recurring adjusted² Operating income up 20.2% y-o-y

Recurring adjusted³ fully diluted EPS (Group share) up 7.1% y-o-y

Good cash generation: €134.7m generated by operating activities during H1 2010

Solid balance sheet : €142.1m positive net cash position at June 30, 2010

NOTE 1 : at constant exchange currency


NOTE 2 : Defined as reported operating income before any impacts related to purchase price accounting in connection with the Group's acquisitions and before any potential non-recurring items.

NOTE 3 : Reported Diluted Earnings Per Share excluding (i) any non recurring impacts and (ii) the net impacts of the purchase price accounting related to the Group's acquisitions



Today, Ipsen has a well balanced therapeutic footprint





45



	H1 2009	Actuals	H1 2010	Actuals	OBI-1 costs /rebillings
- In million of euros	Value	% Sales	Value	% Sales	Non-recurring revenues
Sales	521.2	100.0%	553.9	100.0%	• 2009 : €36,4m • 2010 : -
Other revenues	51.9	10.0%	31.7	5.7%	OBI-1 rebilling (Inspiration)
Total revenues	573.1	110%	585.7	105.7%	• 2009 : - • 2010 : €6,8m
Cost of goods sold	-115.3	-22.1%	-122.6	-22.1%	PPA adjustments
Research & Development expenses	-91.5	-17.6%	-99.1	-17.9%	• 2009 : €-0,7m • 2010 : -
Selling expenses	-186.1	-35.7%	-203.9	-36.8%	OBI-1 development costs • 2009 : €0m
General and administrative expenses	-44.8	-8.6%	-43.6	-7.9%	• 2010 : €-6,8m
Other operating income and expenses	-4.8	-0.9%	-4.7	-0.9%	Non-recurring costs • 2009 : -
Amortizations of intangible fixed assets	-5.5	-1.1%	-6.0	-1.1%	 2010 : €-2,7m PPA adjustments
Restructuring costs	-	-	-0.9	-0.2%	2009 : €-4,6m 2010 : €-4,6m
Operating income	125.2	24.0%	104.9	18.9%	Non-recurring costs
Pecurring adjusted operating income $^{(1)}$	94 1	18 1%	1122	20 1%	• 2009 : -

94.1

18.1%

⁽¹⁾ Excluding royalties received from Bayer (€36,4m in 2009 vs €0m in 2010), impacts of PPA and some others non recurring costs

20.4%

113.2

• 2010 : €-0,9m

Recurring

Adjusted

Recurring adjusted operating income ⁽¹⁾



Recurring Adjusted

	H12009 Actuals		H1 2010 A	ctuals	
- In million of euros	Value	% Sales	Value	% Sales	
Operating income	125.2	24.0%	104.9	18.9%	Kogenate ro
Operating income adjusted recurring ⁽¹⁾	94.1	18.1%	113.2	20.4%	rate: 27%
Net finance cost and other expenses	-4.7	-0.9%	-3.8	-0.7%	
ncome tax	-22.0	-4.2%	-20.7	-3.7%	\langle
Effective tax of continuing operations	18.2%		20.4%		
Share of - loss/profit of associated companies	-	-	-5.1	-0.9%	
venues from continuing operations	98.5	18.9%	75.4	13.6%	PPA tax rat
Revenues from discontinued operations	0.5	0.1%	0.2	0.0%	
nsolidated net profit	99.1	19.0%	75.6	13.6%	
nsolidated net profit - Group share	98.7		75.5		
arning per share - fully diluted	1.17		0,89		
curring adjusted consolidated result	75.7		80,8		
ecurring adjusted earning per share - lly diluted	0,90		0.96		

47

(1) Excluding royalties received from Bayer (€36,4m in 2009 vs €0m in 2010), impacts of PPA and some others non recurring costs.